D

테고사이언스

191420KOSDAQ기초 의약물질 제조업

38.0 / 100

Reference Date: 2026-04-13

Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Declined 14.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.

Number of Employees

40people

Average Salary

48.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 33.454.0Point
PBR
1.92Industry Average 2.034.0Point

In line with industry avg

ROE
-14.04Industry Average -4.293.5Point

3.3x industry avg (excellent)

Debt Ratio
47.88Industry Average 6.610.0Point

7.2x industry avg (risky)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼12.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼93.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.0% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 11,940Won52-week high 19,79052-week low 11,620
1-month return1.0Point

1m -14.65% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral정기주주총회결과2026-03-27
  • Neutral사업보고서 (2025.12)2026-03-19
  • Neutral감사보고서제출2026-03-19